Literature DB >> 14991584

Site-specific familial aggregation of prostate cancer.

Bas A J Verhage1, Katja K H Aben, J Alfred Witjes, Huub Straatman, Jack A Schalken, Lambertus A L M Kiemeney.   

Abstract

Over the last decade, epidemiologic evidence has accumulated in favor of a significant but heterogeneous hereditary component in prostate cancer (PC) susceptibility. In order to map and clone PC susceptibility genes, stratification of PC families into genetically homogeneous groups appears to be a key issue. Subset definition based on age at diagnosis, presumed mode of inheritance, number of affecteds per family and coaggregation of PC with other cancers has already proven successful in some studies. Previously, the finding of the coaggregation of malignancies of the central nervous system within PC families helped to link a prostate-brain cancer susceptibility gene (CAPB) to chromosome 1p36. In this study, we evaluate the risk of PC and malignancies at other sites among first-degree relatives of a large population-based group of Dutch PC patients. A population-based family case-control study was initiated that included Caucasian PC patients newly diagnosed between July 1996 and December 1999. Information on 12,575 first-degree relatives of 704 PC patients and 1,371 controls was collected through postal questionnaires and telephone interviews. All reported PC in first-degree relatives was verified through medical records. In our population, PC has a strong familial component that is reflected by a 2.9-fold increased risk (95% CI = 2.2-3.9) of PC for first-degree relatives of PC patients. This familial risk was somewhat higher among brothers (hazard ratio = 3.9; 95% CI = 2.4-6.4) compared to fathers (hazard ratio = 2.5; 95% CI = 1.7-3.6). Cancers at other sites did not coaggregate with PC. Our data suggest that familial PC, at least in this Western European population, is site-specific, not part of an inherited cancer syndrome. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14991584     DOI: 10.1002/ijc.20015

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Epidemiology of Prostate and Testicular Cancer.

Authors:  Pauline Filippou; James E Ferguson; Matthew E Nielsen
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

Review 2.  Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.

Authors:  Timothy R Rebbeck
Journal:  Semin Radiat Oncol       Date:  2016-08-26       Impact factor: 5.934

Review 3.  Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.

Authors:  Timothy R Rebbeck
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

4.  Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort-an aggressive pathology and a strong familial link.

Authors:  Usman M Haroon; Shona O'Grady-Coyne; Niall F Davis; Christian Gullmann; James C Forde; Gordon P Smyth; Richard E Power; Ijaz A Cheema; Liza McLornan
Journal:  Prostate Int       Date:  2020-02-25

5.  The effect of a school-based educational intervention on gender differences in reported family cancer history.

Authors:  John M Quillin; Joann N Bodurtha; Donna K McClish; Kristyn N Hoy; Ian J Wallace; Alice Westerberg; Steven J Danish
Journal:  J Cancer Educ       Date:  2008       Impact factor: 2.037

6.  An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis.

Authors:  Michał Kiciński; Jaco Vangronsveld; Tim S Nawrot
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

7.  The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.

Authors:  J Melia; D Dearnaley; S Moss; L Johns; P Coulson; C Moynihan; J Sweetman; M C Parkinson; R Eeles; M Watson
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

Review 8.  Recent Insights on Genetic Testing in Primary Prostate Cancer.

Authors:  Mona Kafka; Cristian Surcel; Isabel Heidegger
Journal:  Mol Diagn Ther       Date:  2021-06-12       Impact factor: 4.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.